Portola hires Lonza for AndexXa supply under Swiss CMO's Ibex service
Portola Pharmaceuticals Inc has hired Lonza to make AndexXa (andexanet alfa), the candidate anticoagulation antidote it resubmitted for US FDA review last month.
Archives for September 5, 2017
GE launches cell therapy thawing tech
GE Healthcare has launched a thawing technology for cell therapies it says removes the risks and inconsistencies of standard water baths.
Roche to up Russian Gazyva supply through local fill/finish deal
Local manufacturer Pharmstandard will make the finished dosage form of Roche’s monoclonal antibody Gazyva (obinutuzumab) at its site in Ufa.
Update
Spain OKs TiGenix's bigger cell therapy plant as firm preps for Cx601
Spain has licensed TiGenix NV's expanded Madrid plant paving the way for a potential European launch of Cx601, its cell therapy for the Crohn's disease complications.